Biotech Values

[DewDiligence]

Do you buy what ANDS is saying about 3 patients in the placebo arm achieving eCVR between weeks 10 and 12 skewing the results in favor of placebo?

I don’t see why this ought to be considered skewing of the data in the control arm.

Thanks for posting the webcast slides.